Robin's team conducted clinical trials to evaluate the efficacy of MEK inhibitors in the downstream signaling pathway of KRAS in combination with pan-HER-2 inhibitors in KRASG12C-mutant tumor groups. This evidence concerns the gene KRAS and neoplasm.